卡铂联合培美曲塞序贯培美曲塞维持对比多西他赛单药一线治疗老年晚期非鳞NSCLC的3期随机试验
该开放标签、多中心、非劣效性3期随机试验在日本79家机构纳入433例≥75岁、ECOG 0-1、未接受过细胞毒化疗的晚期非鳞NSCLC患者,比较卡铂+培美曲塞4周期后培美曲塞维持与多西他赛单药的疗效与安全性。
要点
- 卡铂-培美曲塞序贯维持方案在老年晚期非鳞NSCLC一线治疗中对OS非劣于多西他赛单药。
- 卡铂-培美曲塞组中位OS 18.7个月,多西他赛组15.5个月,分层HR 0.850(95%CI 0.684-1.056)。
- 卡铂-培美曲塞组3/4级白细胞减少、中性粒细胞减少及发热性中性粒细胞减少发生率低于多西他赛组。
核心结论
- 对于≥75岁晚期非鳞NSCLC患者,卡铂联合培美曲塞后培美曲塞维持一线治疗在OS上非劣于多西他赛单药,是有效的一线治疗选择。
研究设计与样本
- 开放标签、多中心、非劣效性3期随机临床试验,在日本79家机构开展,2013年8月至2017年2月入组。
- 纳入433例未接受过细胞毒化疗、ECOG PS 0或1、年龄≥75岁的晚期非鳞NSCLC患者,随机接受多西他赛单药(n=217)或卡铂+培美曲塞序贯培美曲塞维持(n=216)。
主要发现
- 卡铂-培美曲塞组PFS更长,非分层HR 0.739(95%CI 0.609-0.896)。
- 卡铂-培美曲塞组3/4级白细胞减少(28.0% vs 68.7%)、中性粒细胞减少(46.3% vs 86.0%)及发热性中性粒细胞减少(4.2% vs 17.8%)发生率低于多西他赛组。
- 卡铂-培美曲塞组3/4级血小板减少(25.7% vs 1.4%)与贫血(29.4% vs 1.9%)发生率高于多西他赛组,剂量下调较少。
关键数值与推荐
- 非劣效性界值为分层Cox模型估计的HR 95%CI上限1.154。
- 多西他赛60 mg/m2每3周;卡铂AUC 5联合培美曲塞500 mg/m2每3周共4周期,后以同剂量培美曲塞维持3周方案。
临床怎么用
- 对≥75岁、PS 0-1的晚期非鳞NSCLC患者,可考虑卡铂联合培美曲塞序贯培美曲塞维持作为一线治疗。
- 用药时注意监测血小板减少与贫血,多西他赛方案则需关注白细胞减少与发热性中性粒细胞减少。
局限性
- 研究仅在日本开展,结果外推至其他人群需谨慎。
- 为开放标签设计,且仅纳入ECOG PS 0或1的老年患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Few clinical trials have been specifically designed for elderly patients with advanced non-small cell lung cancer (NSCLC), and the anticipated increase in the number of such patients has prompted a search for new treatment options that provide a greater palliative benefit. OBJECTIVE: To determine whether treatment with carboplatin plus pemetrexed followed by pemetrexed maintenance is noninferior compared with docetaxel monotherapy with regard to overall survival (OS) for elderly patients with advanced nonsquamous NSCLC. DESIGN, SETTING, AND PARTICIPANTS: This open-label, multicenter, noninferiority phase 3 randomized clinical trial was conducted at 79 institutions in Japan. Cytotoxic chemotherapy-naive patients with advanced nonsquamous NSCLC, an Eastern Cooperative Oncology Group performance status of 0 or 1, and age of 75 years or older were enrolled between August 2013 and February 2017. Data were analyzed from November 2018 to February 2019. INTERVENTIONS: Patients were randomized to receive either docetaxel monotherapy (60 mg/m2) every 3 weeks or 4 cycles of carboplatin (area under the curve of 5) plus pemetrexed (500 mg/m2) administered every 3 weeks followed by maintenance therapy with the same dose of pemetrexed for 3 weeks. MAIN OUTCOMES AND MEASURES: The primary end point was OS analyzed on an intention-to-treat basis with a noninferiority margin of 1.154 for the upper limit of the 95% CI of the hazard ratio (HR) estimated with a stratified Cox regression model. RESULTS: Of the 433 enrolled patients, 250 (57.7%) were male, and the median (range) age was 78 (75-88) years. The median OS was 15.5 months (95% CI, 13.6-18.4) in the docetaxel group (n = 217) and 18.7 months (95% CI, 16.0-21.9) in the carboplatin-pemetrexed group (n = 216), with a stratified HR for OS of 0.850 (95% CI, 0.684-1.056; P for noninferiority = .003). Progression-free survival was also longer in the carboplatin-pemetrexed group (unstratified HR, 0.739; 95% CI, 0.609-0.896). Compared with those in the docetaxel group, those in the carboplatin-pemetrexed had lower rates of leukopenia (60 of 214 [28.0%] vs 147 of 214 [68.7%]) and neutropenia (99 of 214 [46.3%] vs 184 of 214 [86.0%]) of grade 3 or 4 and of febrile neutropenia (9 of 214 [4.2%] vs 38 of 214 [17.8%]) and higher rates of thrombocytopenia (55 of 214 [25.7%] vs 3 of 214 [1.4%]) and anemia (63 of 214 [29.4%] vs 4 of 214 [1.9%]) of grade 3 or 4. Dose reductions were less frequent with carboplatin-pemetrexed. CONCLUSION AND RELEVANCE: Carboplatin-pemetrexed treatment followed by pemetrexed maintenance is a valid option for first-line treatment of elderly patients with advanced nonsquamous NSCLC. TRIAL REGISTRATION: University Hospital Medical Information Network Clinical Trials Registry Identifier: UMIN000011460.
引用
- Okamoto I, Nokihara H, Nomura S, et al. Comparison of Carboplatin Plus Pemetrexed Followed by Maintenance Pemetrexed With Docetaxel Monotherapy in Elderly Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020. PMID: 32163097. doi:10.1001/jamaoncol.2019.6828
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。